November 17, 2026, (Inside AI) — Isomorphic Labs, the AI drug discovery firm spun out of Google DeepMind, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. The London-based company announced the funding on Tuesday, confirming its second mega-round in six months. It declined to disclose its valuation.
The raise follows a $2.1 billion Series B in May, led by Thrive Capital. That round itself came just over a year after Isomorphic's first external funding. The pace signals both investor appetite for AI-driven biotech and the capital intensity of pushing experimental molecules toward human trials.
Isomorphic is using the money to move its first drug candidates into clinical trials. The company has not named those candidates or the diseases they target. That silence is notable in a sector where preclinical milestones often arrive with press releases and partnership announcements.
Why Two Rounds In Six Months?
The Series C is not a sign of distress but of ambition. Drug discovery is expensive, and AI does not change that. Training large models on molecular data requires massive compute, and validating predictions in the lab requires wet-lab infrastructure and staff. Isomorphic is building both.
Read: Baidu CEO AI Bubble Warning
The company's edge rests on AlphaFold, DeepMind's protein-structure prediction system. AlphaFold solved a decades-old biology problem by predicting how proteins fold from their amino acid sequences. Isomorphic applies that capability to drug design, aiming to identify molecules that bind to disease targets with high precision.
But protein folding is only one piece. A drug must also be safe, absorbable, and manufacturable. AI can narrow the search space, yet clinical trials remain the ultimate test. No AI-designed drug has yet won regulatory approval, and the field's track record is short.
That gap between prediction and proof explains the funding pattern. Investors are not betting on a proven product. They are betting on a platform that could compress timelines and cut failure rates. The $5 billion gives Isomorphic runway to run multiple trials in parallel, a strategy that could accelerate learning but also multiply risk.
The round's co-leads carry weight. Greenoaks is known for concentrated bets on high-growth technology companies. Sequoia Capital has backed biotech and AI firms across stages. Their joint leadership suggests conviction in Isomorphic's internal pipeline, not just its partnership potential.
Isomorphic has existing deals with Eli Lilly and Novartis, signed in 2024. Those partnerships provided upfront payments and milestone fees. The new capital reduces reliance on such deals and gives the company more control over which programs it advances internally.
Alphabet remains a backer. The parent company's involvement gives Isomorphic access to Google's compute infrastructure and talent pool. It also raises questions about independence. Isomorphic operates as a separate entity, but its deepest technical roots run through DeepMind.
Read: Nvidia Turmoil Ends Easy Money
The funding landscape for AI biotech has cooled from its 2021 peak. Several startups that promised AI-first drug discovery have struggled to show clinical results. Isomorphic's raise stands out because it is one of the few firms with a foundational technology, AlphaFold, that the broader scientific community has validated.
Still, validation of a tool is not validation of a drug. Isomorphic's first trial readouts will be the real test. The company has not set a timeline for those readouts. That absence of detail is common at this stage but leaves investors and observers guessing about the pace of progress.
The Series C brings Isomorphic's total disclosed funding to over $7 billion in under two years. For context, that exceeds the total venture funding raised by many publicly traded biotech companies over their entire histories. The comparison underscores how much capital AI drug discovery now commands, and how much expectation rides on a handful of clinical bets.
Isomorphic's next move will be watched closely. If its candidates enter trials smoothly, the company could set a benchmark for AI-designed drugs. If they stumble, the sector's already cautious investors may pull back further. Either way, the $5 billion ensures Isomorphic will be central to that story.
Shamil has a low tolerance for AI that only works in controlled demos. He covers agentic systems and generative AI with the skepticism of someone who has seen too many “revolutionary” tools quietly disappear six months after launch.